Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewXanomeline oxalate
Description: Functionally selective M1 agonist
Chemical Name: 3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridine oxalate
Purity: ≥98% (HPLC)
Biological Activity for Xanomeline oxalate
Xanomeline oxalate is a functionally selective muscarinic M1 receptor agonist (EC50 values are 0.3, 5, 42, 52 and 92.5 nM at M1, M3, M5, M4 and M2 receptors respectively). Displays a complex pharmacological profile: reversible and wash-resistant binding, resulting in full agonist activity at M1; delayed wash-resistant partial agonist activity at M2; and delayed wash-resistant full agonist activity at M4. Exhibits antipsychotic activity, and improves cognitive deficits and behavioral disturbances in Alzheimer's disease and schizophrenia.
Compound Libraries for Xanomeline oxalate
Xanomeline oxalate is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
Technical Data for Xanomeline oxalate
| M. Wt | 371.46 |
| Formula | C14H23N3OS.C2H2O4 |
| Storage | Desiccate at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 141064-23-5 |
| PubChem ID | 18920248 |
| InChI Key | ZJOUESNWCLASJP-UHFFFAOYSA-N |
| Smiles | CCCCCCOC1=NSN=C1C2=CCCN(C)C2.OC(C(O)=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Xanomeline oxalate
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 3.71 | 10 with gentle warming | |
| DMSO | 37.15 | 100 |
Preparing Stock Solutions for Xanomeline oxalate
The following data is based on the product molecular weight 371.46. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.69 mL | 13.46 mL | 26.92 mL |
| 5 mM | 0.54 mL | 2.69 mL | 5.38 mL |
| 10 mM | 0.27 mL | 1.35 mL | 2.69 mL |
| 50 mM | 0.05 mL | 0.27 mL | 0.54 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Xanomeline oxalate
References for Xanomeline oxalate
References are publications that support the biological activity of the product.
Jakubik et al (2008) Importance and prospects for design of selective muscarinic agonists. Physiol.Res. 57 S39 PMID: 18481916
Heinrich et al (2009) Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur.J.Pharmacol. 605 53 PMID: 19168056
Stanhope et al (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J.Pharmacol.Exp.Ther. 299 782 PMID: 11602695
If you know of a relevant reference for Xanomeline oxalate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Xanomeline oxalate, Xanomeline oxalate supplier, Functionally, selective, M1, agonists, Muscarinic, Receptors, Acetylcholine, ACh, 3569, Tocris Bioscience
1 Citation for Xanomeline oxalate
Citations are publications that use Tocris products. Selected citations for Xanomeline oxalate include:
Tian et al (2016) STEP activation by Gαq coupled GPCRs opposes Src regulation of NMDA receptors containing the GluN2A subunit Scientific Reports 6 36684 PMID: 27857196
Do you know of a great paper that uses Xanomeline oxalate from Tocris? Please let us know.
Reviews for Xanomeline oxalate
There are currently no reviews for this product. Be the first to review Xanomeline oxalate and earn rewards!
Have you used Xanomeline oxalate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Alzheimer's Disease PosterNew
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Cardiovascular Poster
Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.